Drugs in Dev. Cardiology/Vascular Diseases
IND Enabling
Japan 
Lead Product(s) : HS-001
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : UTokyo Innovation Platform
Deal Size : $37.0 million
Deal Type : Series C Financing
Details : Heartseed plans to use the new funds to accelerate the initiation of global clinical trial of our lead asset, HS-001 for HF as well as to confirm its proof of concept in Phase 1/2 LAPiS study in Japan.
Product Name : HS-001
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
November 06, 2021
Lead Product(s) : HS-001
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : UTokyo Innovation Platform
Deal Size : $37.0 million
Deal Type : Series C Financing
Lead Product(s) : HS-001
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Novo Nordisk
Deal Size : $598.0 million
Deal Type : Collaboration
Details : HS-001 is an investigational cell therapy using purified cardiomyocytes derived from induced pluripotent stem cells. Heartseed is planning to initiate a phase 1/2 clinical trial in Japan in the second half of 2021.
Product Name : HS-001
Product Type : Cell and Gene therapy
Upfront Cash : $55.0 million
January 06, 2021
Lead Product(s) : HS-001
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Novo Nordisk
Deal Size : $598.0 million
Deal Type : Collaboration
Reset All
